Interest of fluoxetine in obsessive-compulsive disorders in adults: A review;Intérêt de la fluoxétine dans les troubles obsessionnels et compulsifs de l'adulte: Revue de la littérature

Encephale

Volumn 27, Issue 3, 2001, Pages 280-289

  Etain, B ^a   Bonnet Perrin, E ^b  

^a PERCY MILITARY HOSPITAL   (France)

^b Laboratoires Lilly France   (France)

Author keywords

Fluoxetine; Obsessive compulsive disorder; Review

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; SEROTONIN;

ARTICLE; BEHAVIOR THERAPY; CAUDATE NUCLEUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; META ANALYSIS; OBSESSION; ORBITAL CORTEX; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; SCORING SYSTEM; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; TREATMENT OUTCOME;

EID: 0034924009     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder
2. Side effects as predictors of drug response in obsessive-compulsive disorder
3. A comprehensive psychopathological rating scale
4. Current treatments of the anxiety disorders in adults
5. Role of serotonin in obsessive compulsive disorder
6. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder
7. Fluoxetine: No association with suicidality in obsessive-compulsive disorder
8. Sertraline and fluoxetine treatment of OCD: A 6-month, double-blind, parallel study
9. Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder
10. A double-blind comparison of sertraline and clomipramine in out-patients with obsessive-compulsive disorder
11. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses
12. Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders
13. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder
14. FDG-PET predictors of response to behavioral therapy and pharmacotherapy in obsessive-compulsive disorder
15. Clomipramine in the treatment of patients with obsessive-compulsive disorder
16. Clomipramine, fluoxetine and behavioral therapy in the treatment of obsessive compulsive disorder: A meta-analysis
17. SCL-90: An outpatient psychiatric rating scale: Preliminary report
18. Serotoninergic antidepressants and their efficacity in obsessive-compulsive disorder
19. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors
20. Treatment of obsessive-compulsive disorder
21. Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies
22. Fluoxetine in the treatment of obsessive-compulsive disorder
23. Fluoxetine in the long term maintenance of obsessive-compulsive disorder
24. Efficacity of long term fluoxetine treatment of obsessive compulsive disorder
25. The Yale-Brown Obsessive Compulsive Scale. Development, use and reliability
26. Efficacity and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder - A meta-analysis
27. Pharmacotherapy for obsessive-compulsive disorder
28. A rating scale for depression
29. Troubles obsessionnels et compulsifs: Place de la fluoxétine
30. Aspects cliniques des troubles et des syndromes obsessionnels et compulsifs: Résultats de la phase 2 d'une large enquête française
31. Evaluation répétée de l'impulsivité dans une cohorte de 155 patients souffrant d'un trouble obsessionnel compulsif: Suivi prospectif de 12 mois
32. Prévalence des troubles obsessionnels compulsifs dans une large population française de patients consultants en psychiatrie
33. Obsessive-compulsive disorder, depression and fluoxetine
34. Open trial of fluoxetine in obsessive-compulsive disorder
35. Clomipramine versus fluoxetine in obsessive-compulsive disorder: A retrospective comparison of side effects and efficacity
36. Recent developments in neurobiology of obsessive-compulsive disorder
37. Placebo controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder
38. The epidemiology of obsessive-compulsive disorder in five US communities
39. Open fixed dose trial of fluoxetine in the treatment of obsessive-compulsive disorder
40. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder?
41. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder
42. Obsessive compulsive disorder: Pathogenesis and fluoxetine treatment
43. Long term fluoxetine treatment of a large number of obsessive-compulsive patients
44. Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial
45. Double blind comparison of fluoxetine versus clomipramine in the treatment of obsessive-compulsive disorder
46. Functional anatomy of obsessive-compulsive disorder
47. Use of factor-analysed symptom dimensions to predict outcome with serotonine reuptake inhibitors and placebo in the treatment of obsessive compulsive disorder
48. Absence of placebo response in OCD
49. The relationship of plasma clomipramine and N-desmethylclomipramine to response in obsessive-compulsive disorder
50. A double blind, placebo controlled study of fluoxetine in patients with DSM IIIR obsessive compulsive disorder
51. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder
52. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder
53. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation
54. Beyond depression: Citalopram for obsessive-compulsive disorder
55. Efficacity of drug treatment in obsessive-compulsive disorder: A meta analysis review
56. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder
57. OCD: Where the serotonin selectivity story begins
58. Predictors of drug treatment response in obsessive-compulsive disorder
59. Long term management of obsessive-compulsive disorder
60. Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder
61. A review of multicenter controlled studies of fluoxetine versus imipramine and placebo in outpatients with major depressive disorder
62. Meta analysis of pharmacotherapy trials for obsessive-compulsive disorder
63. Cerebral glucose metaolism in childhood-onset obsessive-compulsive disorder: Revisuaization during pharmacotherapy
64. Continuation treatment of OCD: Double blind and open label experience with fluoxetine
65. Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders
66. A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder
67. Fluoxetine treatment of obsessive compulsive disorder
68. Side effect profile and safety of fluoxetine
69. Neurobiology of anxiety disorders: Focus on neuroimaging
70. Fluoxetine and obsessive-compulsive disorder: A naturalistic study
71. Pharmacotherapy of obsessive-compulsive disorder - Experience with fluoxetine
72. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder
73. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder